TY - JOUR
T1 - Safety and efficacy of phage therapy in difficult-to-treat infections
T2 - a systematic review
AU - Uyttebroek, Saartje
AU - Chen, Baixing
AU - Onsea, Jolien
AU - Ruythooren, Fred
AU - Debaveye, Yves
AU - Devolder, David
AU - Spriet, Isabel
AU - Depypere, Melissa
AU - Wagemans, Jeroen
AU - Lavigne, Rob
AU - Pirnay, Jean Paul
AU - Merabishvili, Maya
AU - De Munter, Paul
AU - Peetermans, Willy E.
AU - Dupont, Lieven
AU - Van Gerven, Laura
AU - Metsemakers, Willem Jan
N1 - Publisher Copyright:
© 2022 Elsevier Ltd
PY - 2022/8
Y1 - 2022/8
N2 - According to the latest reports from WHO, the incidence of antibiotic-resistant bacterial infections is increasing worldwide, resulting in increased morbidity and mortality and a rising pressure on health-care systems. However, the development of new antibiotics is an expensive and time-consuming process, urging scientists to seek alternative antimicrobial strategies. Over the past few decades, the concept of therapeutic administration of bacteriophages (also known as phages) has gained popularity worldwide. Although conceptually promising, the widespread implementation of phage therapy in routine clinical practice is restricted by the scarcity of safety and efficacy data obtained according to the strict standards of the applicable clinical trial regulations. In this systematic review, we list clinical data published between Jan 1, 2000 and Aug 14, 2021 on the safety and efficacy of phage therapy for difficult-to-treat bacterial infections, and provide an overview of trials and case studies on the use of phage therapy in several medical disciplines.
AB - According to the latest reports from WHO, the incidence of antibiotic-resistant bacterial infections is increasing worldwide, resulting in increased morbidity and mortality and a rising pressure on health-care systems. However, the development of new antibiotics is an expensive and time-consuming process, urging scientists to seek alternative antimicrobial strategies. Over the past few decades, the concept of therapeutic administration of bacteriophages (also known as phages) has gained popularity worldwide. Although conceptually promising, the widespread implementation of phage therapy in routine clinical practice is restricted by the scarcity of safety and efficacy data obtained according to the strict standards of the applicable clinical trial regulations. In this systematic review, we list clinical data published between Jan 1, 2000 and Aug 14, 2021 on the safety and efficacy of phage therapy for difficult-to-treat bacterial infections, and provide an overview of trials and case studies on the use of phage therapy in several medical disciplines.
UR - http://www.scopus.com/inward/record.url?scp=85112198818&partnerID=8YFLogxK
U2 - 10.1016/S1473-3099(21)00612-5
DO - 10.1016/S1473-3099(21)00612-5
M3 - Review article
C2 - 35248167
AN - SCOPUS:85112198818
SN - 1473-3099
VL - 22
SP - e208-e220
JO - The Lancet Infectious Diseases
JF - The Lancet Infectious Diseases
IS - 8
ER -